Treatment effectiveness in advanced breast cancer patients in Italy: Ten years experience.
Sandro Barni, Elena Collovà(Aziende Socio Sanitarie Territoriale Ovest Milanese), Marta Bonotto(University of Udine), Fabio Puglisi(University of Udine), Chiara Saggia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Daniele Generali(University of Trieste), I. Vallini(Ospedale di Circolo e Fondazione Macchi), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Valentina Fausti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vittorina Zagonel(Istituto Oncologico Veneto), Karen Borgonovo(Azienda Ospedaliera Treviglio), Francesco Massari(Altera (United States)), Luca Porcu(Mario Negri Institute for Pharmacological Research), Marzia Di Pietro Paolo, Monica Indelli, Antonella Brunello(Istituto Oncologico Veneto), Anna Moretti(ASST Fatebenefratelli Sacco), Graziella Pinotti(Medica (Italy)), Maria Cristina Petrella
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751